The Use of Allogeneic Leukocytes Infusion in Cancer Immunotherapy

Authors

  • Yishu Tang
  • Chunxia Zhou
  • Wenbo Ma
  • Dongmei Wang
  • Shuren Zhang

Abstract

Mixed allogeneic lymphocyte response has activated considering T lymphocytes and elicit type 1 cytokines which induced antitumor immunity. Using TC-1 cancer model, we demonstrated the response of inactivated allogeneic leukocytes infusion (ALI) to generate antitumor immune response. In TC-1 tumor model, ALI induced a delayed cancer development and a prolonged survival. Our study illustrated that ALI might elicit strong antitumor immune response. The method strategy would be easy and efficient strategy in tumor immunotherapy.

Downloads

Published

2018-05-30

How to Cite

Tang, Y., Zhou, C., Ma, W., Wang, D., & Zhang, S. (2018). The Use of Allogeneic Leukocytes Infusion in Cancer Immunotherapy. Archives of Clinical and Biomedical Research, 2(4), 151–155. Retrieved from https://fortunejournals.org/ojs/index.php/acbr/article/view/14722